In vitro and in vivo effects of P-MAPA immunomodulator on schistosomiasis.
Acta Trop
; 218: 105909, 2021 Jun.
Article
in En
| MEDLINE
| ID: mdl-33789153
ABSTRACT
Schistosomiasis is an infectious disease caused by helminth parasites of the genus Schistosoma; it is transmitted in over 78 countries. The main strategy for schistosomiasis control is treatment of infected people with praziquantel (PZQ). As PZQ-resistant strains have emerged, new anti-schistosomal agents have become necessary. We evaluated the in vitro and in vivo effect of P-MAPA, an aggregated polymer of protein magnesium ammonium phospholinoleate-palmitoleate anhydride with immunomodulatory properties; it is produced by Aspergillus oryzae fermentation. In vitro, P-MAPA (5, 50, and 100 µg/mL) damaged the Schistosoma mansoni tegument, causing thorn losses and tuber destruction in male worms and peeling and erosion in females after 24-h incubation. In vivo, P-MAPA (5 and 100 mg/kg, alone and combined with PZQ - 50 mg/kg) reduced the number of eggs by up to 69.20% in the liver and 88.08% in the intestine. Furthermore, granulomas were reduced up to 83.13%, and there was an increase in the number of dead eggs and a reduction of serum aspartate aminotransferase levels. These data suggest that P-MAPA activity can help improve schistosomiasis treatment and patients' quality of life.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Praziquantel
/
Schistosoma mansoni
/
Schistosomiasis mansoni
/
Linoleic Acids
/
Oleic Acids
Aspects:
Patient_preference
Limits:
Animals
/
Female
/
Humans
/
Male
Language:
En
Journal:
Acta Trop
Year:
2021
Document type:
Article
Affiliation country:
Brasil